{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:32Z","timestamp":1753891952610,"version":"3.41.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012569","name":"University of Toledo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00472","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T04:50:56Z","timestamp":1586321456000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential Use of Sofosbuvir in the Prophylaxis for Rabies"],"prefix":"10.3389","volume":"11","author":[{"given":"Sandra E.","family":"Reznik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit K.","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Charles R.","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.coviro.2014.08.006","article-title":"Targeting structural dynamics of the RNA-dependent RNA polymerase for anti-viral strategies","volume":"9","author":"Boehr","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S1473-3099(11)70340-1","article-title":"Passive immunity in the prevention of rabies","volume":"12","author":"Both","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1128\/AAC.01922-15","article-title":"Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus","volume":"60","author":"Feng","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1124\/dmd.117.079038","article-title":"The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection","volume":"46","author":"Garrison","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003786","article-title":"Correction: Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PloS Negl. Trop. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.idc.2012.05.001","article-title":"Rabies: relevance, prevention, and management in travel medicine","volume":"26","author":"Hatz","year":"2012","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/cid\/ciu012","article-title":"Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries","volume":"58","author":"Hill","year":"2014","journal-title":"Clin. Infect. Dis."},{"article-title":"Rabies Immune Globulin (Human), Imogam\u00ae Rabies","volume-title":"Aventis Pasteur.","year":"2005","key":"B8"},{"key":"B9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.virusres.2011.09.025","article-title":"Structural insights into the rhabdovirus transcription\/replication complex","volume":"162","author":"Ivanov","year":"2011","journal-title":"Virus Res."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002032","article-title":"Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis","volume":"13","author":"Iyengar","year":"2016","journal-title":"PloS Med."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139001","article-title":"Structural Analysis of Monomeric RNA-Dependent Polymerases: Evolutionary and Therapeutic Implications","volume":"10","author":"Jacome","year":"2015","journal-title":"PloS One"},{"key":"B12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/jtm.12024","article-title":"The global availability of rabies immune globulin and rabies vaccine in clinics providing direct care to travelers","volume":"20","author":"Jentes","year":"2013","journal-title":"J. Travel Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40265-014-0179-7","article-title":"Sofosbuvir: first global approval","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3201\/eid1809.111833","article-title":"Inadequate antibody response to rabies vaccine in immunocompromised patient","volume":"18","author":"Kopel","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.cell.2015.06.018","article-title":"Structure of the L Protein of Vesicular Stomatitis Virus from Electron Cryomicroscopy","volume":"162","author":"Liang","year":"2015","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9961","DOI":"10.1074\/jbc.M113.542761","article-title":"Sensitivity of the polymerase of vesicular stomatitis virus to 2\u2032 substitutions in the template and nucleotide triphosphate during initiation and elongation","volume":"289","author":"Morin","year":"2014","journal-title":"J. Biol. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1592\/phco.29.10.1182","article-title":"Overview, prevention, and treatment of rabies","volume":"29","author":"Nigg","year":"2009","journal-title":"Pharmacotherapy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.antiviral.2016.12.021","article-title":"Substrate selectivity of Dengue and Zika virus NS5 polymerase towards 2\u2032-modified nucleotide analogues","volume":"140","author":"Potisopon","year":"2017","journal-title":"Antiviral Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1056\/NEJMcp042140","article-title":"Clinical practice. Prophylaxis against rabies","volume":"351","author":"Rupprecht","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"E4005","DOI":"10.1073\/pnas.1602591113","article-title":"Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation","volume":"113","author":"Shu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"B22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cell.2016.08.044","article-title":"Enter Sofosbuvir: The Path to Curing HCV","volume":"167","author":"Sofia","year":"2016","journal-title":"Cell"},{"volume-title":"Product information. Sovaldi (sofosbuvir)","year":"2015","key":"B23"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1007\/s00018-014-1695-z","article-title":"Common and unique features of viral RNA-dependent polymerases","volume":"71","author":"Te Velthuis","year":"2014","journal-title":"Cell Mol. Life Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/INF.0000000000000641","article-title":"The \u201cMilwaukee protocol\u201d for treatment of human rabies is no longer valid","volume":"34","author":"Wilde","year":"2015","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1056\/NEJMoa050382","article-title":"Survival after treatment of rabies with induction of coma","volume":"352","author":"Willoughby","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B27","first-page":"1","article-title":"WHO Expert Consultation on Rabies. Second report","volume":"983","author":"World Health","year":"2013"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/infdis\/jiv586","article-title":"Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis","volume":"213","author":"Yamada","year":"2016","journal-title":"J. Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1017\/cjn.2015.331","article-title":"Critical Appraisal of the Milwaukee Protocol for Rabies: This Failed Approach Should Be Abandoned","volume":"43","author":"Zeiler","year":"2016","journal-title":"Can. J. Neurol. Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00472\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T04:50:58Z","timestamp":1586321458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00472\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":29,"alternative-id":["10.3389\/fphar.2020.00472"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00472","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2020,4,8]]},"article-number":"472"}}